EUVIMEDEUVIMED entdecken
Crossref

Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso‐Occlusive Pain

Ugochukwu Agbakwuru, Jacob D AuBuchon, Bobi Toebe, Anne LaBarge, Jorge Di Paola, Monica L Hulbert iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Ugochukwu Agbakwuru und 5 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Lidocaine, Analgesics, Opioid, Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: ASH Minority Resident Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) vaso‐occlusive episode (VOE) pain is treated with opioids, and non‐opioid adjuvants may reduce pain severity without opioid side effects. We retrospectively investigated the safety and tolerability of intravenous lidocaine infusions as an adjunct to opioids in children and adolescents during VOE hospitalizations. In 2 years, lidocaine was administered in 64.6% of 260 admissions. There were no serious toxicities; overall, 82.2% of recipients chose to receive lidocaine during subsequent admissions. Lidocaine infusions were associated with longer hospitalizations, potentially reflecting selection bias. The efficacy of adjuvant lidocaine infusions during VOE should be studied prospectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellLidocaineAnalgesics, OpioidPainAnesthetics, LocalHumansMaleChildFemaleAdolescentInfusions, IntravenousRetrospective StudiesChild, PreschoolHospitalizationFollow-Up StudiesPain ManagementPrognosis

Stichwörter der Autor:innen

opioidpain managementsickle cell diseasevaso‐occlusive pain

Substanzen

LidocaineAnalgesics, OpioidAnesthetics, Local

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
  • Department of Anesthesiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Monica L Hulbert

Förderung

  • ASH Minority Resident Award

Zitieren

APA

Agbakwuru, U., AuBuchon, J. D., Toebe, B., LaBarge, A., Di Paola, J., & Hulbert, M. L. (2025). Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso‐Occlusive Pain. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31458

Vancouver

Agbakwuru U, AuBuchon JD, Toebe B, LaBarge A, Di Paola J, Hulbert ML. Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso‐Occlusive Pain. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31458

BibTeX
@article{Agbakwuru2025,
  author = {Agbakwuru, Ugochukwu and AuBuchon, Jacob D and Toebe, Bobi and LaBarge, Anne and Di Paola, Jorge and Hulbert, Monica L},
  title = {Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle Cell Vaso‐Occlusive Pain},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31458}
}
Kostenlos starten →